Navigation Links
Prometheus Licenses COLAL-PRED(R) From Alizyme
Date:11/29/2007

rometheuslabs.com.

About Alizyme plc

Alizyme is a specialty biopharmaceutical development company, focused on the therapeutic areas of metabolic disorders, gastrointestinal disorders and cancer supportive care. In addition to COLAL-PRED, it is developing cetilistat for the treatment and management of obesity and related diseases, such as Type II diabetes, renzapride for the treatment of irritable bowel syndrome ("IBS"), and ATL-104 for mucositis, a side effect of cancer therapy.

COLAL-PRED is the combination of Alizyme's proprietary colonic drug delivery system, COLAL, and prednisolone metasulfobenzoate sodium ("PMSBS"), an approved steroid in Europe. COLAL-PRED has a starch coating that is only broken down in the gut by bacteria occurring in the colon. This leads to topical delivery of PMSBS to the colon rather than systemic delivery with the objective of providing efficacy, but without the side effects of steroids; however, the efficacy and safety of COLAL-PRED must be shown in well-controlled, prospective clinical trials and approved by the FDA.

COLAL is a drug delivery technology which enables drugs to be taken orally, but then be specifically released in the colon. Achieving colonic release with conventional oral dosage forms has proven difficult because of the variation between individuals in transit times and conditions within the gastrointestinal tract. COLAL overcomes this difficulty by covering small pellets containing the drug with a coating of ethylcellulose and a specific form of amylose (derived from starch). This coating prevents drug release in the stomach and small intestine. When the pellets reach the colon, the amylose in the coating is broken down by bacterial enzymes and the drug is released.

This press release contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to various risks, and Prometheus
'/>"/>

SOURCE Prometheus Laboratories Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
2. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
3. Medinet Licenses MaxCyte Cell Loading Technology for Cancer Immunotherapy in Japan
4. Codexis Licenses New Drug Metabolite Profiling and Lead Diversification Technology From the California Institute of Technology
5. Southern Research Institute Licenses Anti-Cancer Drug Compound to Virium Pharmaceuticals
6. Protherics Licenses its CoVaccine HT Adjuvant to Nobilon for Influenza Vaccine Indications
7. HUYA Bioscience International Licenses Clinical Stage Anti-Arrhythmic Compound from the Shanghai Institute of Materia Medica
8. Syngenta Licenses Chromatin Gene Stacking Technology
9. Utrecht University Licenses MetaDrug From GeneGo for Drug Innovation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... -- PharmaBoardroom,s new report, , Healthcare ... for free download , digs deep into this vibrant ... the sector today. One area where ... developing a homegrown pharmaceutical manufacturing base, even if the government,s ... way off. A cursory comparison with neighboring Morocco ...
(Date:12/24/2014)... NEW YORK , Dec. 23, 2014 ... pilot study of mazindol in children with attention deficit/hyperactivity ... in December 2014 . The paper, ... with attention deficit/hyperactivity disorder" ( Konofal et al, ... 1;8:2321-2332. eCollection 2014 ) shows that mazindol might ...
(Date:12/22/2014)... RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: RP), a ... of autologous cell therapies, announced today the publication of ... conjunction with co-authors from Kyoto University and the University ... clinical research using dermal sheath cup (DSC) cells to ... paper entitled " Hair Follicle Dermal Stem Cells Regenerate ...
(Date:12/22/2014)... , Dec. 22, 2014  ( www.competitivehealth.com ) ... an online medical bill review and advocacy service, has ... the FREE WellCard Savings discount health services marketplace. ... that was more than they expected to pay. As ... health care costs, WellCard Savings is pleased to offer ...
Breaking Biology Technology:PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2
... LA JOLLA, Calif., Jan. 17, 2012  Synthetic Genomics Inc. ... solutions to solve a wide range of global challenges, ... Vice President for Nutritional Products. Stagnitti is a proven ... translating these into high value food and nutritional products ...
... Jan. 17, 2012 Reliv International, Inc. (NASDAQ: ... of LunaRich™, an exclusive soy powder developed at the Missouri ... of its nutritional supplements and will reveal that product at ... "Biotechnology is vital to Missouri,s economic future," said ...
... Inc. (NASDAQ: VVUS ) today announced that ... The Journal of Sexual Medicine (JSM), a peer-reviewed ... randomized, placebo-controlled, phase 3 study evaluating the safety and ... by the Food and Drug Administration (FDA) for the ...
Cached Biology Technology:Synthetic Genomics Inc. Hires Industry Leader George E. Stagnitti to Head Food and Nutritional Products Development Program 2Reliv and Soy Labs Launch LunaRich, a Healthier Soy 2Reliv and Soy Labs Launch LunaRich, a Healthier Soy 3Reliv and Soy Labs Launch LunaRich, a Healthier Soy 4REVIVE Trial Results for Avanafil Published in JSM Demonstrate Significant Improvement in Erectile Function 2REVIVE Trial Results for Avanafil Published in JSM Demonstrate Significant Improvement in Erectile Function 3REVIVE Trial Results for Avanafil Published in JSM Demonstrate Significant Improvement in Erectile Function 4REVIVE Trial Results for Avanafil Published in JSM Demonstrate Significant Improvement in Erectile Function 5REVIVE Trial Results for Avanafil Published in JSM Demonstrate Significant Improvement in Erectile Function 6
(Date:12/17/2014)... -- Automation is fundamentally transforming the travel experience and ... borders. Over the past decade, ePassports, biometric readers, ... to self process through border control via eGates ... increasing number of airports, seaports, and land borders ... Maxine Most , Principal at Acuity Market ...
(Date:12/11/2014)... 2014  Data Sciences International (DSI), the global ... new series of digital telemetry implants to meet ... series, part of the PhysioTel™ Digital platform, was ... physiologic data when incorporating functional endpoints into repeat-dose ... toxicology studies has evolved from short ECG strips ...
(Date:12/10/2014)... Dec. 08, 2014 Research and Markets ... of the "Biometrics Market in Japan 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 The integration ... as rural banking and upgradation of the driver,s ... in the market. Besides the aforementioned projects, biometrics ...
Breaking Biology News(10 mins):Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2New telemetry implants expected to change how large animal toxicology studies are conducted 2Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2
... aimed at preventing cervical cancer is nearly 100 percent effective ... for most cases of cervical cancer. Results of a nationwide ... 9 issue of the New England Journal of Medicine. , ... deaths in women worldwide, resulting in nearly half a million ...
... helping to build a compelling case for oncolytic ... many cancers. , Reovirus, a non-pathogenic ... has shown powerful anti-cancer activity against cultured tumor ... trials. Oncolytics' proprietary reovirus formulation, Reolysin®, is active ...
... Universitat Autònoma de Barcelona, in cooperation with the animal ... model which faithfully reproduces the characteristics of dog’s skin ... various lines of research related to skin biology and ... The basic structure of skin consists of an external ...
Cached Biology News:Study shows continued success for new HPV vaccine against virus responsible for cervical cancer 2Dealing deadly cancers a knockout punch 2Dealing deadly cancers a knockout punch 3
Human M-CSF...
Human Serpin B5/Maspin Affinity Purified Polyclonal Ab...
... and S.J. Allen (1995) This ... world authorities on current issues relating to ... Several major advances have been made recently ... disease. Topics include molecular neuropathology through clinical ...
Normal human serum, single donor...
Biology Products: